Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896446 | 0.88 | EGFR (0.40) | ADORA2AADORA1RAB9ALMNAMEN1 | |
| SCHEMBL13815653 | 0.86 | KMT2A (0.39) | NPC1RAB9ATP53LMNAMEN1 | |
| SCHEMBL13815722 | 0.76 | SMN1; SMN2 (0.42) | ADORA2AADORA1NPC1RAB9ATP53 | |
| SCHEMBL13815652 | 0.70 | NPC1 (0.40) | ADORA2AADORA1NPC1RAB9ATP53 | |
| SCHEMBL13896445 | 0.68 | F2 (0.46) | LMNAMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL18294025 | 0.64 | HTT (0.75) | NPC1RAB9ATP53LMNAMEN1 | |
| SCHEMBL13815624 | 0.63 | PIK3CD (0.41) | RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL10522910 | 0.62 | ADORA2A (0.44) | ADORA2AADORA1TP53MEN1ALDH1A1 | |
| SCHEMBL9621602 | 0.61 | SMN1; SMN2 (0.57) | ADORA2AADORA1LMNAMEN1ALDH1A1 | |
| SCHEMBL9621703 | 0.60 | ADORA2A (0.44) | ADORA2AADORA1TP53LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314098-B2 | Pyrazolo-pyrimidine compounds | AJINOMOTO CO., INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | IL23R, IL2, IL17A | ADORA2A 849/4885ADORA1 1551/4885NPC1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.